Page last updated: 2024-08-23

bucindolol and Atrial Fibrillation

bucindolol has been researched along with Atrial Fibrillation in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (90.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Abraham, WT; Aleong, R; Anand, IS; Bristow, MR; Camm, AJ; Carroll, IA; Connolly, SJ; Dufton, C; Healey, JS; Khaykin, Y; Krueger, SK; Marshall, D; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Ziegler, PD1
Parikh, KS; Piccini, JP1
Abraham, WT; Al-Khalidi, HR; Aleong, RG; Anand, IS; Bristow, MR; Clark, RL; Connolly, SJ; Davis, GW; Dignacco, P; Dufton, C; Emery, LL; Healey, JS; Marshall, DA; Piccini, JP; Sauer, WH; Steinberg, BA; van Veldhuisen, DJ; White, M; Wilton, SB1
Abraham, WT; Aleong, R; Anand, IS; Ayala-Paredes, F; Bristow, MR; Carroll, IA; Connolly, SJ; Davis, G; Dufton, C; Emery, LL; Healey, JS; Ilkhanoff, L; Kao, DP; Khaykin, Y; Krueger, SK; Marshall, D; Merkely, B; Miloradović, V; Piccini, JP; Rienstra, M; Sauer, WH; van Veldhuisen, DJ; White, M; Wilton, SB; Wranicz, JK; Ziegler, PD1
Metra, M; Shah, P1
Abraham, WT; Aleong, RG; Anand, IS; Bristow, MR; Davis, G; Fiuzat, M; Liggett, SB; Murphy, GA; O'Connor, CM; Port, JD; Sauer, WH1
Aleong, RG; Bristow, MR; Davis, G; Sauer, WH1
Black-Maier, E; Piccini, JP; Steinberg, BA1
Brunelli, C; Ferrero, S; Meliota, G; Rosa, GM1
Aleong, R; Anand, IS; Bristow, MR; Carson, PE; Davis, G; Fiuzat, M; Gottlieb, SS; Kao, DP; Lindenfeld, J; Miller, AB; Murphy, GA; O'Connor, CM; Plehn, JF; Sauer, W; Silver, MA; White, M1

Reviews

3 review(s) available for bucindolol and Atrial Fibrillation

ArticleYear
Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure.
    Current heart failure reports, 2017, Volume: 14, Issue:6

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Genotype; Heart Failure; Humans; Pharmacogenetics; Propanolamines; Receptors, Adrenergic, beta-1; Stroke Volume

2017
Bucindolol hydrochloride in atrial fibrillation and concomitant heart failure.
    Expert review of cardiovascular therapy, 2015, Volume: 13, Issue:6

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Heart Failure; Humans; Pharmacogenetics; Polymorphism, Genetic; Propanolamines; Receptors, Adrenergic, beta-1

2015
Pharmacokinetic drug evaluation of bucindolol for the treatment of atrial fibrillation in heart failure patients.
    Expert opinion on drug metabolism & toxicology, 2017, Volume: 13, Issue:4

    Topics: Adrenergic beta-Antagonists; Animals; Atrial Fibrillation; Heart Failure; Hospitalization; Humans; Propanolamines; Receptors, Adrenergic, alpha-2; Receptors, Adrenergic, beta-1

2017

Trials

6 trial(s) available for bucindolol and Atrial Fibrillation

ArticleYear
Bucindolol Decreases Atrial Fibrillation Burden in Patients With Heart Failure and the
    Circulation. Arrhythmia and electrophysiology, 2021, Volume: 14, Issue:8

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Follow-Up Studies; Genotype; Heart Failure; Humans; Male; Propanolamines; Receptors, Adrenergic, beta-1; Time Factors

2021
A genotype-directed comparative effectiveness trial of Bucindolol and metoprolol succinate for prevention of symptomatic atrial fibrillation/atrial flutter in patients with heart failure: Rationale and design of the GENETIC-AF trial.
    American heart journal, 2018, Volume: 199

    Topics: Adrenergic alpha-1 Receptor Antagonists; Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; DNA; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Genetic Testing; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Stroke Volume; Treatment Outcome

2018
Bucindolol for the Maintenance of Sinus Rhythm in a Genotype-Defined HF Population: The GENETIC-AF Trial.
    JACC. Heart failure, 2019, Volume: 7, Issue:7

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Electrocardiography; Female; Genotype; Heart Failure; Humans; Male; Metoprolol; Middle Aged; Mortality; Pharmacogenetics; Pharmacogenomic Variants; Precision Medicine; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Stroke Volume

2019
Prevention of atrial fibrillation by bucindolol is dependent on the beta₁389 Arg/Gly adrenergic receptor polymorphism.
    JACC. Heart failure, 2013, Volume: 1, Issue:4

    Topics: Adrenergic beta-Antagonists; Atrial Fibrillation; Female; Heart Failure; Humans; Male; Middle Aged; Polymorphism, Genetic; Propanolamines; Prospective Studies; Receptors, Adrenergic, beta-1; Treatment Outcome

2013
New-onset atrial fibrillation predicts heart failure progression.
    The American journal of medicine, 2014, Volume: 127, Issue:10

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Disease Progression; Female; Heart Failure; Humans; Male; Middle Aged; Multivariate Analysis; Prognosis; Propanolamines; Proportional Hazards Models; Risk Factors; Ventricular Dysfunction, Left

2014
Effect of bucindolol on heart failure outcomes and heart rate response in patients with reduced ejection fraction heart failure and atrial fibrillation.
    European journal of heart failure, 2013, Volume: 15, Issue:3

    Topics: Adrenergic beta-Antagonists; Aged; Atrial Fibrillation; Case-Control Studies; Drug Resistance; Female; Heart Failure; Heart Rate; Hospitalization; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Polymorphism, Single Nucleotide; Propanolamines; Proportional Hazards Models; Receptors, Adrenergic, beta-1; Retrospective Studies; Treatment Outcome

2013

Other Studies

1 other study(ies) available for bucindolol and Atrial Fibrillation

ArticleYear
GENETIC-AF: Digging Deeper Into Genotype-Phenotype and Heart Failure-Atrial Fibrillation Interactions.
    JACC. Heart failure, 2019, Volume: 7, Issue:7

    Topics: Atrial Fibrillation; Genotype; Heart Failure; Humans; Phenotype; Propanolamines

2019